Display options
Cite
Ceulemans F, Humblet Y, Bosly A, et al. A phase I study of vinblastine tryptophan ester. Cancer Chemother Pharmacol. 1986;18(1):44-6doi: 10.1007/BF00253062.
Ceulemans, F., Humblet, Y., Bosly, A., Symann, M., & Trouet, A. (1986). A phase I study of vinblastine tryptophan ester. Cancer chemotherapy and pharmacology, 18(1), 44-6. https://doi.org/10.1007/BF00253062
Ceulemans, F, et al. "A phase I study of vinblastine tryptophan ester." Cancer chemotherapy and pharmacology vol. 18,1 (1986): 44-6. doi: https://doi.org/10.1007/BF00253062
Ceulemans F, Humblet Y, Bosly A, Symann M, Trouet A. A phase I study of vinblastine tryptophan ester. Cancer Chemother Pharmacol. 1986;18(1):44-6. doi: 10.1007/BF00253062. PMID: 3757158.
Copy Download .nbib Format: NLM
Share it on

Cancer Chemother Pharmacol. 1986;18(1):44-6. doi: 10.1007/BF00253062.

A phase I study of vinblastine tryptophan ester.

Cancer chemotherapy and pharmacology

F Ceulemans, Y Humblet, A Bosly, M Symann, A Trouet

PMID: 3757158 DOI: 10.1007/BF00253062

Abstract

Vinblastine tryptophan ester (VTrpE) is a new vinca alkaloid derivative that achieves antitumor activity in a large variety of animal models. In this phase I study the drug was given as an i.v. injection over 5 min, once a week or once every 2 weeks. Twenty patients with advanced cancer were entered in this trial. The doses ranged from 2.5 mg/m2 to 35 mg/m2. Myelosuppression is the dose-limiting toxicity, with the risk of leukopenia being more serious than that of thrombocytopenia, but the myelosuppression is always reversible. Neurotoxicity, well documented when other vinca alkaloid derivatives are used, is insignificant. Two cases of disease stabilization have been observed in patients with non-small cell lung cancer. For VTrpE, a dose schedule of 30 mg/m2 per week may be recommended for phase II studies in non-small cell lung cancer.

References

  1. Cancer. 1968 Aug;22(2):467-72 - PubMed
  2. N Engl J Med. 1974 Jun 11;291(2):75-81 - PubMed
  3. Cancer Res. 1973 Jun;33(6):1258-64 - PubMed
  4. Neurology. 1969 Apr;19(4):367-74 - PubMed
  5. Arch Intern Med. 1965 Dec;116(6):846-52 - PubMed
  6. Anticancer Res. 1985 Jul-Aug;5(4):379-86 - PubMed
  7. J Med Chem. 1985 Aug;28(8):1079-88 - PubMed
  8. Cancer Treat Rep. 1979 Aug;63(8):1343-6 - PubMed
  9. J Med Chem. 1978 Jan;21(1):88-96 - PubMed
  10. Semin Oncol. 1982 Mar;9(1):103-30 - PubMed
  11. Cancer Res. 1963 Sep;23:1390-427 - PubMed

Substances

MeSH terms

Publication Types

LinkOut - more resources